The combination of the CCR1 antagonist CCX9588 with an anti-PD-L1 antibody has shown promise as a therapeutic approach, synergistically inhibiting primary tumor growth and lung metastasis in an in situ breast cancer mouse model (51). This evidence concerns the gene CD274 and breast cancer.